The <i>NPM1</i> Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

<div><p><i>NPM1</i> mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a favorable prognosis. Different types of <i>NPM1</i> mutations have been described. The purpose of our study was to evaluate the relevance of different <i>NPM1</i> mutation types with regard to clinical outcome. Our analyses were based on 349 <i>NPM1</i>-mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were not significantly different between patients with <i>NPM1</i> type A or rare type mutations. The <i>NPM1</i> mutation type does not seem to play a role in risk stratification of cytogenetically normal AML.</p>